



FACULDADE DE MEDICINA  
UNIVERSIDADE DE  
COIMBRA

MESTRADO INTEGRADO EM MEDICINA – TRABALHO FINAL

ANDRÉ LUÍS SILVA DO CARMO

***COVID-19 impact on liver transplantation recipients***

ARTIGO DE REVISÃO SISTEMÁTICA

ÁREA CIENTÍFICA DE CIRURGIA GERAL

Trabalho realizado sob a orientação de:

DULCE HELENA SARAMAGO DIOGO CORTES

CRISTIANA DE CAMPOS MARQUES

ABRIL/2021

# **TITLE: COVID-19 IMPACT ON LIVER TRANSPLANTATION RECIPIENTS**

**Author:** André Luís Silva do Carmo

**Filiation:** Faculty of Medicine, University of Coimbra, Coimbra, Portugal

**Electronic Mail Address:** andre.carmo.porto@gmail.com

**Adviser:** Dulce Helena Saramago Diogo Cortes

**Filiation:** Adult Liver Transplantation Unit, Coimbra Hospital and University Center, Coimbra, Portugal

**Electronic Mail Address:** dudiago@gmail.com

**Co-adviser:** Cristiana de Campos Marques

**Filiation:** Faculty of Psychology and Educational Sciences, Center for Research in Neuropsychology and Cognitive Behavioural Intervention (CINEICC), University of Coimbra, Coimbra, Portugal

**Electronic Mail Address:** cristiana.c.marques@hotmail.com

## INDEX

List of abbreviations.....	4
Abstract.....	6
Resumo.....	7
Introduction.....	8
Materials and Methods	
<i>Study identification</i> .....	9
<i>Study selection</i> .....	9
<i>Statistical analysis</i> .....	10
Results	
<i>Adult population</i> .....	11
<i>Pediatric population</i> .....	19
Discussion.....	21
Acknowledgments.....	25
References.....	25

## **LIST OF ABBREVIATIONS**

**AHT** – arterial hypertension  
**AI** – autoimmune;  
**AKI** – acute kidney injury;  
**ALF** – acute liver failure;  
**ALT** – alanine aminotransferase;  
**ARDS** – acute respiratory distress syndrome;  
**AST** – aspartate aminotransferase;  
**AZA** – azathioprine;  
**BiPAP** – bilevel positive airway pressure;  
**BNP** – brain natriuretic peptide;  
**CKD** – chronic kidney disease;  
**CNI** – calcineurin inhibitor;  
**COPD** – chronic obstructive pulmonary disease;  
**COVID-19** – coronavirus infectious disease 2019;  
**CPAP** – continuous positive airway pressure;  
**CRP** – C-reactive protein;  
**CVD** – cardiovascular disease;  
**DM** – diabetes mellitus;  
**EBV** – Epstein-Barr virus;  
**ECMO** – extracorporeal membrane oxygenation;  
**EVE** – everolimus;  
**GGT** – gamma-glutamyltransferase;  
**HBV** – hepatitis B virus;  
**HCC** – hepatocellular carcinoma;  
**HCQ** – hydroxychloroquine;  
**HCV** – hepatitis C virus;  
**HIV** – human immunodeficiency virus;  
**ICU** – intensive care unit;  
**INF-a** – interferon alpha;  
**IFN-b** – interferon beta;  
**IL** – interleukin;  
**IS** – immunosuppression;  
**LMWH** – low molecular weight heparin;  
**LT** – liver transplantation;  
**MeSH** – medical subject headings;

**MMF** – mycophenolate mofetil;  
**MPA** – mycophenolic acid;  
**mTOR** – mammalian target of rapamycin;  
**NASH** – nonalcoholic steatohepatitis  
**NS** – not specified;  
**PCR** – polymerase chain reaction;  
**PICO** – population, intervention, control/comparison, outcome;  
**PHEIC** – public health emergency of international concern;  
**PRISMA** – preferred reporting items for systematic reviews and meta-analyses;  
**PSC** – primary sclerosing cholangiopathy;  
**ReTx** – re-transplantation;  
**rhG-CSF** – recombinant human granulocyte colony-stimulating factor;  
**SARS-CoV-2** – severe acute respiratory syndrome coronavirus 2;  
**SIR** – sirolimus;  
**SOB** – shortness of breath;  
**SOFA** – Sequential Organ Failure Assessment;  
**SpO<sub>2</sub>** – peripheral oxygen saturation;  
**STEMI** – ST elevated myocardial infarction;  
**TAC** – tacrolimus;  
**tBRB** – total bilirubin;  
**UK** – United Kingdom;  
**USA** – United States of America;  
**WBC** – white blood cells;  
**WHO** – World Health Organization.

## 1. ABSTRACT

**Introduction:** Since the beginning of the coronavirus infectious disease (COVID-19) pandemic and the fact that liver transplantation (LT) recipients are an immunosuppressed population, a discussion was started if this population was at larger risk of contracting the disease. Many risk factors for disease severity and mortality were proposed however, there is still controversy for this theme and also for the management of the baseline immunosuppression (IS) regimen and target therapy for COVID-19.

**Objectives:** The present work intends to analyze a set of clinical cases and series to conclude on demographic risk factors, baseline regimen and management of the IS, specific therapy for COVID-19 and outcome of these patients.

**Materials and Methods:** A research in MEDLINE and PubMed databases was conducted. A total of 127 articles were identified and 55 included for the final quantitative analysis. The exclusion criteria were: (1) data impossible to differentiate; (2) epidemiological studies; (3) pharmacological studies; (4) surveys; and (5) data unrelated to LT. Statistical analysis was conducted using the chi-square test, spearman rho correlation and logistic regression. Descriptive analyses were presented in number, percentage or mean, standard deviation and range.

**Results:** A total of 111 single cases were analyzed (95 adults and 16 pediatric). Regarding the adult population, 66 (69.47%) were male and the mean age was 58,73 years. The most common comorbidities were obesity/overweight (35.79%), arterial hypertension (33.68%) and diabetes (27.37%). The most used immunosuppressant was tacrolimus (TAC; 74.74%) and mycophenolate mofetil (45.26%). Forty-one patients (43.16%) presented complications during treatment and 12 (12.63%) required invasive ventilation. The mortality rate in the adult population was 20%. Regarding the pediatric population, seven (43.75%) were male and the mean age was 1.28 years. The most used immunosuppressant was TAC (93.75%). Only four patients (25%) presented complications and three (18.75%) required invasive ventilation. Overall mortality for the pediatric population was 18.75%.

**Discussion:** Justifications were presented, based on the literature, for the main statistically significant associations. Whenever possible, comparisons were made with other works similar to the one carried out. Special emphasis was given to comorbidities and immunosuppression.

**Conclusion:** Older age, diabetes, higher white blood cells and support ventilation were associated with worse outcome. Lymphopenia and higher C-reactive protein levels were associated with a severe course of the disease. MMF as a baseline immunosuppression regimen was associated with shock during hospital stay. Overall, the mortality rate was superior in LT recipients than in the general population.

**Keywords:** Liver transplantation; Recipients; COVID-19.

## 2. RESUMO

**Introdução:** Dado o início da pandemia da COVID-19 e ao facto de os recetores de transplantação hepática serem uma população imunodeprimida, iniciou-se discussão se esta se tratava, ou não, de uma população de risco. Foram propostos vários fatores de risco para gravidade de doença e mortalidade, no entanto ainda existe controvérsia não só quanto a este tema, como também relativamente ao manuseamento da imunossupressão de manutenção e terapia específica para a COVID-19.

**Objetivos:** O presente trabalho pretende analisar um conjunto de casos clínicos e séries clínicas de forma a tirar conclusões sobre fatores demográficos de risco, imunossupressão de base e manuseamento da mesma, terapia específica para a COVID-19 e resultado destes doentes.

**Materiais e Métodos:** Foi realizada uma pesquisa nas bases de dados MEDLINE e PubMed. Um total de 127 artigos foram identificados e 55 incluídos na análise quantitativa final. Os critérios de exclusão foram: (1) informação impossível de diferenciar; (2) estudos epidemiológicos; (3) estudos farmacológicos; (4) questionários; e (5) informação não relacionada com transplantação hepática. Utilizou-se os testes chi-quadrado, correlação de spearman e regressão logística para a análise estatística. As análises descritivas são apresentadas com número e percentagem, juntamente com média e intervalo de alcance.

**Resultados:** Cento e onze casos clínicos foram analisados (95 adultos e 16 pediátricos). No que diz respeito à população adulta, 66 (69.47%) eram do sexo masculino e a média da idade foi de 58.73 anos. A comorbilidade mais comum foi obesidade/excesso de peso (35.79%), hipertensão arterial (33.68%) e diabetes (27.37%). Os imunossupressores mais utilizados foram o tacrolimus (TAC; 74.74%) e o micofenolato mofetil (45.26%). Quarenta e um doentes (43.16%) apresentaram complicações durante o tratamento e 12 (12.63%) necessitaram de ventilação invasiva. A taxa de mortalidade referente à população adulta foi de 20%. Quanto à população pediátrica, sete (43.75%) eram do sexo masculino e a idade média foi de 1.28 anos. O imunossupressor mais utilizado foi o TAC (93.75%). Apenas quatro doentes (25%) apresentaram complicações e três (18.75%) precisaram de ventilação invasiva. A mortalidade da população pediátrica foi de 18.75%.

**Discussão:** Foram apresentadas justificações, baseadas na literatura, para as principais associações estatisticamente significativas. Sempre que possível foram estabelecidas comparações com outros trabalhos semelhantes ao efetuado. Foi dado especial ênfase às comorbilidades e à imunossupressão.

**Conclusão:** Idade avançada, diabéticos, presença de neutrofilia e o uso de ventilação foram associados a pior prognóstico. Elevados níveis de proteína C reativa e de linfopenia foram associados a severidade da doença. O uso de MMF como imunossupressão de base foi associado a choque durante o internamento. A mortalidade dos recetores de transplante hepático infetados com COVID-19 foi superior à mortalidade da população em geral.

**Palavras-chave:** Transplantação hepática; Recetores; COVID-19.

### 3. INTRODUCTION

What was considered as a “viral pneumonia” in Wuhan, China, evolved to a PHEIC and, on 11<sup>th</sup> March 2020, was considered a pandemic by the WHO.<sup>(1)</sup> The etiological agent responsible was identified as severe acute respiratory syndrome coronavirus 2, responsible for coronavirus infectious disease (COVID-19). Until October 7, 2020, there have been reported more than 76 million cases of COVID-19 and more than 1,7 million deaths in 235 countries, areas or territories.<sup>(2)</sup>

The first case of an infection by SARS-CoV-2 in Portugal was confirmed on March 2, 2020<sup>(3)</sup> and, on 18<sup>th</sup> March 2020, the Emergency State was declared for the first time since modern democracy.<sup>(4)</sup> To date, there are 383 258 confirmed cases and 6 413 deaths by COVID-19<sup>(5)</sup> in Portugal.

Many risk factors were associated with a severe SARS-CoV-2 infection in LT recipients. Those are elderly patients (over 60 years old), male gender and one or more comorbidities (such as hypertension, diabetes, COPD, and malignant tumors).<sup>(6-11)</sup> Also, some laboratory results have been independently associated with poor prognosis, being lymphopenia,<sup>(12, 13)</sup> elevated CRP,<sup>(11)</sup> a SOFA score and high d-dimers at admission.<sup>(7)</sup>

Although there is some agreement on the risk factor for disease severity and poor prognosis, when speaking on baseline and IS management there’s still no consensus. On one hand, some authors defend that higher doses of immunosuppressants are at an elevated risk of severe disease,<sup>(14)</sup> and, on the other hand, others present that long term LT recipients on low IS doses, results in prolonged shedding and, consequently, an increase of viral loads and severe clinical presentation, not directly related to the IS.<sup>(15, 16)</sup> Moreover, some physicians showed that LT recipients are not at a higher risk of contracting COVID-19<sup>(17)</sup> when compared with the general population, while others presented LT recipients are at higher risk.<sup>(18)</sup>

Until this moment, there is no specific therapy for COVID-19. The first drugs used were HCQ and Lopinavir/Ritonavir. Recent studies showed that both therapies are ineffective and should not be used in the treatment neither the prevention of SARS-COV-2 infection.<sup>(19)</sup>



Moreover, HCQ has important drug interactions with cyclosporine, TAC and SIR, and lopinavir/ritonavir with SIR, EVE, TAC and cyclosporine, requiring close surveillance of these drug levels.<sup>(20)</sup> Tocilizumab has shown promising results in reducing mortality of ventilated patients or in patients with severe disease however, phase III studies have not demonstrated the efficacy of this IL-6 inhibitor.<sup>(19)</sup> Other potential pharmacological agents in study are remdesivir, and convalescent plasma.

Due to this urgent need for orientation, we conduct a study on all clinical cases in the literature until December 23<sup>rd</sup>, 2020 and analyze the age, time after liver transplantation, comorbidities, baseline IS regimen, main laboratory findings, IS management during treatment, other pharmacological and COVID-19 treatments, complications during treatment, support ventilation and outcome of all these patients.

## **4. MATERIALS AND METHODS**


### **4.1. Study Identification**

A search within MEDLINE and PubMed databases (<https://pubmed.ncbi.nlm.nih.gov>) was conducted using MeSH terms: “COVID-19” (related MeSH terms are: 2019 novel coronavirus, SARS-CoV-2 infection, 2019-nCoV infection) AND “liver transplantation” AND “recipient” from September 3<sup>rd</sup>, 2020 to 23<sup>rd</sup> December 2020. The database used for this systematic review was MEDLINE-PubMed. All terms used for the PubMed search were developed according to the PICO structure: population, intervention, comparison/control and outcome (PICO). Population: children and adults who were liver transplant recipients and diagnosed with COVID-19. Intervention: children and adults who were liver transplant recipients and diagnosed with COVID-19 that presented complications during treatment, died or were discharged home. Control/Comparison: all cases were compared regarding comorbidities, laboratory findings, therapy received and outcome. Outcome: medical management regarding immunosuppression, infectious therapy, established guidelines or consensus, and survival of COVID-19 liver recipients.

### **4.2. Study Selection**

Case reports, original articles, reviews, correspondence, letters to the editor, clinical randomized controlled trials, non-randomized controlled trials, consensus articles and protocol studies were included. Papers published in languages other than English were translated using the *Google Translate* tool.

Studies on organs other than liver or that the data is impossible to differentiate from the liver transplantation, epidemiological studies, surveys, those on clinical presentation of COVID-19, and those unrelated to liver transplantation were excluded from this meta-analysis. Figure 1 represents a flow diagram on the research, based on the PRISMA<sup>(21)</sup>.



**FIGURE 1.** PRISMA flow diagram for the research.

### 4.3. Statistical Analysis

Statistical analyses were performed using IBM SPSS 25 software.

Descriptive analyses were presented in number and percentage or mean, standard deviation and range.

Chi-square tests were used to test the independence between categorical variables (association between initial symptoms, baseline and management of IS, other pharmacological therapy and support ventilation, with complications and outcome). Spearman rank-order correlations ( $\rho$ ) were used to calculate the strength of the relationship between age and complications, age and outcome, time after LT and complications, and time after LT and

outcome. Logistic regressions were used to test if comorbidities and main laboratory findings have an effect on the presence of complications (yes/no) and outcome (alive/dead) variables. A 95% confidence interval was established.


For all the analyses, a value of  $p < .05$  was considered significant.

## 5. RESULTS

A total of 55 articles were analyzed. Regarding those articles, 111 single cases were reviewed, in which 95 (85.59%) were adult patients and the others 16 (14.41%) were pediatric.

### 5.1. Adult population

Regarding the adult population, 66 (69.47%) were male, 27 (28.42%) female, and 2 (2.11%) cases were not specified. The mean age was 58.73 years ( $SD = 13.57$  years), ranging between 18 and 85 years. The distribution of the population by age and sex is represented in Figure 2. Four (4.21%) patients were white, 1 (1.05%) black, 1 (1.05%) Asian, 1 (1.05%) Indian, 1 (1.05%) Hispanic, 2 African American (2.11%), and 85 (89.47%) were not specified. The mean time from liver transplantation to COVID-19 diagnosis was 6.98 years ( $SD = 7.129$  years), ranging from 0 to 28.2 years. In one case, the time between transplantation to COVID-19 diagnosis was not specified.



**FIGURE 2.** Distribution of the adult population by age and sex.

The most common cause for liver transplantation was HCC ( $n = 20$ ; 21.05%) and HCV infection ( $n = 20$ ; 21.05%), followed by HBV infection ( $n = 14$ ; 14.74%), alcoholic cirrhosis ( $n = 10$ ; 10.53%), and PSC ( $n = 4$ ; 4.21%). The most common comorbidities were overweight/obesity ( $n = 34$ ; 35.79%), AHT ( $n = 32$ ; 33.68%), diabetes mellitus ( $n = 26$ ; 27.37%), CVD ( $n = 15$ ; 15.79%), and CKD ( $n = 14$ ; 14.74%). In 19 (20%) cases there were no comorbidities. The most frequent maintained IS regimen in monotherapy or in combination was TAC ( $n = 71$ ; 74.74%), MMF ( $n = 43$ ; 45.26%), prednisone ( $n = 21$ ; 22.11%), EVE ( $n = 7$ ; 7.37%), and methylprednisolone ( $n = 7$ ; 7.37%). All demographic data are presented in Table 1.

The most prevalent initial symptoms between the adult population were fever ( $n = 63$ ; 66.32%), cough ( $n = 38$ ; 40%), SOB ( $n = 33$ ; 34.74%) and diarrhea ( $n = 20$ ; 21.05%). The mean time from the initial symptoms to hospital admission was 4.35 ( $SD = 6.31$ ) days, ranging from 0 to 40 days. In 38 (40%) cases the time between initial symptoms to hospital admission was not specified.

**TABLE 1.** Demographics for the study population

		<b>Adult cases (n=95)</b> <i>n (%)</i>	<b>Pediatric cases (n=16)</b> <i>n (%)</i>	
<b>Gender</b>	<i>Male</i>	66 (69.47)	7 (43.75)	
	<i>Female</i>	27 (28.42)	9 (56.25)	
	<i>NS</i>	2 (2.11)	0 (0)	
<b>Age</b>	<i>Mean (SD)</i>	58.73 (13.57)	1.28 (1.49)	
	<i>NS</i>	0 (0)	10 (62.5)	
<b>Ethnicity/Race</b>	<i>White</i>	4 (4.21)	4 (25)	
	<i>Black</i>	1 (1.05)	0 (0)	
	<i>Asian</i>	1 (1.05)	0 (0)	
	<i>Hispanic</i>	1 (1.05)	7 (43.75)	
	<i>African American</i>	2 (2.11)	0 (0)	
	<i>Indian</i>	1 (1.05)	0 (0)	
	<i>NS</i>	85 (89.47)	5 (31.25)	
<b>Time after LT</b>	<i>Mean (years)</i>	6.98	3.50	
	<i>NS</i>	1 (1.05)	0 (0)	
<b>Etiology for LT</b>	<i>HCC</i>	20 (21.05)	0 (0)	
	<i>HCV infection</i>	20 (21.05)	0 (0)	
	<i>HBV infection</i>	14 (14.74)	0 (0)	
	<i>Alcoholic cirrhosis</i>	10 (10.53)	0 (0)	
	<i>PSC</i>	4 (4.21)	0 (0)	
	<i>Cryptogenic cirrhosis</i>	3 (3.16)	1 (6.25)	
	<i>NASH</i>	3 (3.16)	0 (0)	
	<i>ALF</i>	3 (3.16)	0 (0)	
	<i>AI hepatitis</i>	2 (2.11)	0 (0)	
	<i>Chronic rejection</i>	2 (2.11)	0 (0)	
	<i>Budd-Chiari Syndrome</i>	2 (2.11)	0 (0)	
	<i>Familial Amyloid Polyneuropathy</i>	1 (1.05)	0 (0)	
	<i>Vasculitis</i>	1 (1.05)	0 (0)	
	<i>Antiretroviral-induced hepatotoxicity</i>	1 (1.05)	0 (0)	
	<i>Biliary atresia</i>	0 (0)	5 (31.25)	
	<i>Hepatic adenomatosis</i>	0 (0)	1 (6.25)	
	<i>Cholestatic liver disease</i>	0 (0)	1 (6.25)	
	<i>NS</i>	32 (33.68)	8 (50)	
	<b>Comorbidities</b>	<i>Overweigh/Obesity</i>	34 (35.79)	3 (18.75)
		<i>AHT</i>	32 (33.68)	2 (12.5)
<i>DM</i>		26 (27.37)	2 (12.5)	
<i>CVD</i>		15 (15.79)	0 (0)	
<i>CKD</i>		14 (14.74)	1 (6.25)	
<i>Lung disease</i>		9 (9.47)	1 (6.25)	
<i>HIV</i>		5 (5.26)	0 (0)	
<i>Others</i>		27 (28.42)	12 (75)	
<i>None</i>		19 (20)	5 (31.25)	
<i>NS</i>		18 (18.95)	1 (6.25)	
<b>Baseline IS regimen</b>		<i>TAC</i>	71 (74.74)	15 (93.75)
		<i>MMF</i>	43 (45.26)	4 (25)
	<i>Prednisone</i>	21 (22.11)	4 (25)	
	<i>EVE</i>	7 (7.37)	0 (0)	
	<i>Methylprednisolone</i>	9 (9.47)	1 (6.25)	
	<i>AZA</i>	6 (6.32)	0 (0)	
	<i>MPA</i>	3 (3.16)	0 (0)	
	<i>Cyclosporine</i>	1 (1.05)	0 (0)	
	<i>Corticosteroid NS</i>	1 (1.05)	3 (18.75)	
	<i>Methotrexate</i>	1 (1.05)	0 (0)	
	<i>SIR</i>	0 (0)	2 (12.5)	
	<i>NS</i>	7 (7.37)	0 (0)	

AHT: arterial hypertension; AI: autoimmune; ALF: acute liver failure; AZA: azathioprine; CKD: chronic kidney disease; CVD: cardiovascular disease; DM: diabetes mellitus; EVE: Everolimus; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IS: immunosuppression; LT: liver transplant; MMF: mycophenolate mofetil; MPA: mycophenolic acid; NASH: nonalcoholic steatohepatitis NS: not specified; PSC: primary sclerosing cholangiopathy; SIR: sirolimus; TAC: tacrolimus.

All laboratory findings correspond to the peak of disease. SpO<sub>2</sub> varied between 50 and 100% ( $M = 87.36\%$ ;  $SD = 10.30\%$ ), hemoglobin from 6.6 to 12.4 g/dL ( $M = 9.81$  g/dL;  $SD = 2.12$  g/dL), WBC between 0.66 and 45.9 x10<sup>9</sup>cells/L ( $M = 7.50$  x10<sup>9</sup>cells/L;  $SD = 8.22$  x10<sup>9</sup>cells/L), lymphocytes from 0.04 to 2.5 x10<sup>9</sup>cells/L ( $M = 0.68$  x10<sup>9</sup>cells/L;  $SD = 0.46$  x10<sup>9</sup>cells/L), platelets from 20 000 to 310 000 cells/ $\mu$ L ( $M = 101 346$  cells/ $\mu$ L;  $SD = 84 805,64$  cells/ $\mu$ L), ALT between 8 and 634 U/L ( $M = 87.04$  U/L;  $SD = 120.27$  U/L), AST from 16 to 770 U/L ( $M = 78.63$  U/L;  $SD = 117.09$  U/L), GGT between 24 and 3211 U/L ( $M = 580.62$  U/L;  $SD = 846.17$  U/L), tBRB from 0.07 to 5.38 mg/dL ( $M = 1.71$  mg/dL;  $SD = 1.76$  mg/dL), CRP between 0.56 and 106.04 mg/dL ( $M = 11.57$  mg/dL;  $SD = 16.61$  mg/dL), IL-6 from 5 to 3385,06 pg/mL ( $M = 665.91$  pg/dL;  $SD = 1130.69$  pg/dL), and ferritin from 18 to 2909 ng/mL ( $M = 1153.95$  ng/mL;  $SD = 896.28$  ng/mL).

Sixteen (16.84%) patients were admitted to the ICU. Immunosuppression was lowered in 13 (13.68%) cases, withdrawn or stopped in 24 (25.26%) cases, added in five (5.26%) patients, not changed in 40 (42.11%) patients, and in 19 (20%) cases the immunosuppression management was not specified. Also, MMF dose was lowered in four (4.21%) cases and withdrawn in 14 (14.74%) cases.


HCQ was administered in 32 (33.68%) patients, antiviral therapy in 16 (16.84%) cases, antibiotics in 30 (31.58%) cases, immunoglobulin in five (5.26%) patients, and corticosteroids in four (4.21%) cases.

Invasive mechanical ventilation was used in 11 (11.58%) patients, facial mask in five (5.26%) patients, nasal cannula in 17 (17.89%) cases, CPAP in three (3.16%) cases, BiPAP in one (1.05%) case, ECMO in one (1.05%) patient, no support ventilation in 31 (32.63%) cases, and ventilation was not specified in 22 (23.16%) patients. Furthermore, 10 out of 11 patients (90.91%) on mechanical ventilation died, two out of five patients (40%) on facial mask also died and the same was observed in one case with CPAP and with ECMO.

During hospital stay, six (6.32%) patients developed ARDS, seven (7.37%) presented pneumonia, two (2.11%) patients refractory shock, three (3.16%) cases of graft dysfunction, four (4.21%) patients developed AKI, 21 (22.11%) patients did not develop any complication, and in 33 (34.74%) cases complications were not specified.

Regarding the outcome, 75 (78.95%) patients were alive, 19 (20%) patients died, and in one (1.05%) case the outcome was not specified. The distribution of death in the adult population by age and sex is represented in Figure 3. The mean time of hospital stay/follow-up was 21.7 days ( $SD = 16.18$  days), ranging from 1 to 75 days. In 38 (40%) cases, the time of hospital stay/follow-up was not specified.

Table 2 presents a summary of each clinical case.



**FIGURE 3.** Distribution of death in the adult population by age and sex.

A significant correlation between age and outcome was identified ( $r_s=-0.235$ ,  $p=0.022$ ), meaning that older age is associated with a worse outcome (death). Moreover, age was also associated with graft rejection ( $r_s=-0.409$ ,  $p<0.001$ ) and with neurological complications ( $r_s=0.315$ ,  $p=0.035$ ), meaning that older age is associated with no graft rejection and with neurological complications.

No statistical association was found between time after LT and the outcome ( $r_s=0.037$ ,  $p=0.726$ ). However, time after LT had significant correlations with graft rejection ( $r_s=-0.362$ ,  $p=0.016$ ) and presence of other complications during treatment ( $r_s=-0.360$ ,  $p=0.016$ ) (except for ARDS, AKI, pneumonia, shock and neurological complications).

Regarding comorbidities, diabetes was associated with a worst outcome ( $B=-2.033$ ,  $p=0.043$ , 95% CI = -54.065; -0.065) and obesity/overweight was associated with a better outcome ( $B=2.528$ ,  $p<0.001$ , 95% CI = 0.000; 89.467). No significant statistical associations were found between all other comorbidities (AHT, CKD, CVD, respiratory disease, gastrointestinal disease and HIV) and between complications during treatment.

MMF as a baseline IS regimen was associated with complications during treatment (60% of the cases with complications were on MMF and 100% of the cases with no complications were not on MMF) and with shock ( $X^2_{[1]} = 5.200$ ,  $p=0.023$ ). An association between AZA and ARDS was found ( $X^2_{[1]} = 5.645$ ,  $p=0.018$ ). Furthermore, statistical significance was found between cyclosporine and AKI ( $X^2_{[1]} = 6.979$ ,  $p<0.001$ ), between methylprednisolone and graft rejection ( $X^2_{[1]} = 10.900$ ,  $p<0.001$ ) and between a corticoid not specified and graft rejection ( $X^2_{[1]} = 8.980$ ,  $p<0.001$ ). No statistical significance was found between any baseline IS regimen and the outcome.

The presence of initial symptoms was associated with complications during treatment when compared to asymptomatic patients ( $\chi^2_{[1]} = 9.124$ ,  $p < 0.001$ ). In fact, some symptoms were associated to specific complications, mainly fever with neurological complications ( $\chi^2_{[1]} = 9.124$ ,  $p < 0.001$ ) and fatigue to AKI ( $\chi^2_{[1]} = 6.723$ ,  $p = 0.01$ ). SOB, cough and headache were also associated with complications in general ( $\chi^2_{[1]} = 8.862$ ,  $p < 0.001$ ;  $\chi^2_{[1]} = 10.820$ ,  $p < 0.001$ ; and  $\chi^2_{[1]} = 4.864$ ,  $p = 0.027$ ; respectively). Regarding the outcome, patients with cough and diarrhea were associated with worst outcome ( $\chi^2_{[1]} = 5.309$ ,  $p = 0.021$ ; and  $\chi^2_{[1]} = 8.594$ ,  $p = 0.003$ ).

Statistical significance was also found between some of the laboratory results and the outcome. A higher level of WBC was associated with a worst outcome ( $B = -0.188$ ,  $p = 0.015$ , 95% CI = 0.713; 0.964) and higher levels of AST were also associated with worst final results ( $B = -0.016$ ,  $p = 0.01$ , 95% CI = 0.971; 0.996). Regarding the significance between main laboratory analyzes and complications, lymphopenia was associated with a severe evolution ( $B = -1.953$ ,  $p = 0.036$ , 95% CI = 0.023; 0.884) as well as higher levels of CRP ( $B = 0.173$ ,  $p = 0.048$ , 95% CI = 1.001; 1.412).

None of the drugs used in other pharmacological therapy (HCQ, tocilizumab, lopinavir/ritonavir, remdesivir, umifenovir, oseltamivir, IFN-a, IFN-b, azithromycin, other antibiotics and fresh convalescence plasma) were associated with the outcome. Nonetheless, the use of other pharmacological therapy was associated with complications in general ( $\chi^2_{[1]} = 4.648$ ,  $p = 0.031$ ). Azithromycin demonstrated a dependency relationship with pneumonia ( $\chi^2_{[1]} = 5.692$ ,  $p = 0.017$ ).

Support ventilation had also shown a statistical dependence on complications during treatment ( $\chi^2_{[1]} = 21.860$ ,  $p < 0.01$ ). In fact, 93.5% of patients with support ventilation developed at least one complication during hospital stay while only 6.5% of the cases with complications were not on support ventilation. Moreover, ventilation and outcome had presented statistical dependence ( $\chi^2_{[1]} = 13.935$ ,  $p < 0.001$ ), with 100% of the patients with no ventilation being alive. Mechanical ventilation was associated with poor outcome ( $\chi^2_{[1]} = 16.593$ ,  $p < 0.001$ ) and ECMO with ARDS ( $\chi^2_{[1]} = 4.971$ ,  $p = 0.026$ ) and AKI ( $\chi^2_{[1]} = 4.971$ ,  $p = 0.026$ ).



**TABLE 2.** Summary of the clinical cases used for the adult population.

Reference	Country	Population	Baseline IS (cases)	Main laboratory analyses (mean)	IS management (cases)	Outcome
<b>Fernández-Ruiz et al.<sup>(22)</sup></b>	Spain	3 males 3 females	EVE (3) TAC (2) MMF (2) Prednisone (1) AZA (1)	Lymphocytes $1.05 \times 10^9/L$ ALT 85.17 U/L CRP 9.78 mg/dL	Stopped EVE (2) Lower TAC dose (2) Stopped MMF (2) Added MMF (1) Added TAC (2) No change (1)	4 alive 2 dead
<b>Zhong Z et al.<sup>(23)</sup> Qin J et al.<sup>(24)</sup></b>	China	1 male	TAC Methylprednisolone	Lymphocytes $0.48 \times 10^9/L$ Platelets 74 000 / $\mu L$ ALT 424 U/L CRP 10.18 mg/dL	Stopped TAC Lower methylprednisolone dose	Alive
<b>Huang JF et al.<sup>(25)</sup></b>	China	1 male	TAC MMF	Lymphocytes $<0.1 \times 10^9/L$ ALT 60 U/L CRP 3.51 mg/dL	Lower TAC dose Lower MMF dose	Dead
<b>Liu B et al.<sup>(26)</sup></b>	China	1 male	TAC	Lymphocytes $0.42 \times 10^9/L$ WBC $5.9 \times 10^9/L$ CRP 3.21 mg/dL	Stopped TAC Added methylprednisolone	Alive
<b>Hammami MB et al.<sup>(27)</sup></b>	USA	1 male	TAC	Lymphocytes $0.65 \times 10^9/L$ Platelets 49 000 / $\mu L$ ALT 27 U/L CRP 1.49 mg/dL	No change	Alive
<b>Lee BT et al.<sup>(28)</sup></b>	USA	26 males 12 females	NS	Only related to the deaths: Lymphocytes $0.64 \times 10^9/L$ ALT 59.57 U/L CRP 13.87 mg/dL	NS	31 alive 7 dead
<b>Hoek RAS et al.<sup>(29)</sup></b>	Netherlands	1 male	TAC	NS	No change	Alive
<b>Kates OS et al.<sup>(30)</sup></b>	USA	1 male	Cyclosporine	Lymphocytes $0.9 \times 10^9/L$ WBC $1.93 \times 10^9/L$ ALT 12 U/L	No change	Alive
<b>Gao F et al.<sup>(31)</sup></b>	China	3 males	TAC (3) MMF (1) Corticosteroids (1)	Lymphocytes $0.59 \times 10^9/L$	Lower TAC dose (1) Lower corticosteroids dose (1) No change (1) IS withdrawal (1)	2 alive 1 dead
<b>Verma A et al.<sup>(32)</sup></b>	UK	5 males	TAC (4) Prednisone (4) MMF (1) AZA (1)	Lymphocytes $0.61 \times 10^9/L$ WBC $4.19 \times 10^9/L$	No change (4) Lower MMF dose (1) Higher prednisone dose (1)	5 alive
<b>Fung M et al.<sup>(33)</sup></b>	USA	1 female	TAC MMF	Lymphocytes $0.54 \times 10^9/L$ WBC $4.9 \times 10^9/L$ Platelets 103 000 / $\mu L$ ALT 14 U/L	No change	Alive
<b>Muller H et al.<sup>(34)</sup></b>	Austria	1 male	TAC MMF	Normal WBC CRP 6.1 mg/dL	No change	Alive
<b>Patrono D et al.<sup>(35)</sup></b>	Italy	8 males 2 females	TAC (10) MMF (5) Prednisone (3) EVE (2) MPA (1)	Lymphocytes $0.71 \times 10^9/L$ WBC $6.68 \times 10^9/L$ ALT 104 U/L CRP 6.19 mg/dL	Stopped TAC (3) No change (3) Stopped MMF (1) Lower MMF dose (1) Lower TAC dose (1) Higher prednisone dose (1) IS withdrawal (1)	8 alive 2 dead
<b>Hann A et al.<sup>(36)</sup></b>	UK	2 males 1 female	TAC (3) AZA (3) Prednisone (2)	NS	NS	2 alive 1 dead
<b>Donato MF et al.<sup>(37)</sup></b>	Italy	6 males 2 females	TAC (7) MMF (6) Prednisone (2)	NS	NS	8 alive
<b>Mehta SA et al.<sup>(38)</sup></b>	USA	2 males 1 female	TAC (3) MMF (2) Prednisone (2)	Lymphocytes $0.60 \times 10^9/L$ WBC $3.13 \times 10^9/L$ CRP 20.83 mg/dL	No change (2) Stopped TAC (1) Stopped MMF (1)	3 alive

<b>Prieto M et al.</b> <sup>(39)</sup>	Italy	1 male	MMF Prednisone	Lymphocytes 0.2 x10 <sup>9</sup> /L WBC 4.9 x10 <sup>9</sup> /L Platelets 48 000 / $\mu$ L ALT 634 U/L Ferritin 783 ng/mL	Added TAC	Alive
<b>Jamir I et al.</b> <sup>(40)</sup>	India	1 male	TAC MMF Methylprednisolone	Lymphocytes 0.11 x10 <sup>9</sup> /L WBC 6.67 x10 <sup>9</sup> /L Platelets 31 114 / $\mu$ L ALT 405 U/L CRP 106.04 mg/dL	Stopped MMF	Alive
<b>Eslami P et al.</b> <sup>(41)</sup>	Iran	1 male	TAC Methylprednisolone	Lymphocytopenia WBC 15.7 x10 <sup>9</sup> /L Platelets 20 000 / $\mu$ L ALT 110 U/L	NS	Dead
<b>García-Juaréz I et al.</b> <sup>(42)</sup>	Mexico	1 female	TAC	Lymphocytes 0.87 x10 <sup>9</sup> /L WBC 2.8 x10 <sup>9</sup> /L Platelets 115 000 / $\mu$ L ALT 13 U/L CRP 3.9 mg/dL	Lower TAC dose	Alive
<b>Hatami B et al.</b> <sup>(43)</sup>	Iran	1 female	TAC MMF Prednisone	WBC 10.1 x10 <sup>9</sup> /L Platelets 310 000 / $\mu$ L ALT 15 U/L CRP 1.8 mg/dL	Stopped MMF	NS
<b>Bosch F et al.</b> <sup>(44)</sup>	Germany	1 male 1 female	MMF (2) EVE (1)	NS	Stopped MMF (1) No change (1)	2 alive
<b>Antony SJ et al.</b> <sup>(45)</sup>	USA	1 male	TAC Prednisone MPA	Lymphocytes 0.2 x10 <sup>9</sup> /L WBC 12.13 x10 <sup>9</sup> /L ALT 64 U/L CRP 3.7 mg/dL	IS withdrawal Added methylprednisolone	Alive
<b>Loinaz C et al.</b> <sup>(46)</sup>	Spain	11 males 2 females	MMF (7) TAC (6) Prednisone (2) EVE (1) MPA (1)	Lymphocytes 0.72 x10 <sup>9</sup> /L WBC 4.54 x10 <sup>9</sup> /L ALT 36.38 U/L CRP 9.67 mg/dL	No change (13)	13 alive
<b>Modi AR et al.</b> <sup>(47)</sup>	USA	1 male	TAC MMF Prednisone	Lymphocytes 1.22 x10 <sup>9</sup> /L WBC 7.41 x10 <sup>9</sup> /L ALT 87 U/L CRP 2 mg/dL	Lower TAC dose Stopped MMF	Alive
<b>Felldin M et al.</b> <sup>(48)</sup>	Sweden	1 male 7 females	TAC (8) MMF (4) Prednisone (3) AZA (1) Methotrexate (1)	NS	No change (4) Stopped MMF (2) Lower MMF dose (1) Stopped methotrexate (1)	7 alive 1 dead
<b>Kolonko A et al.</b> <sup>(49)</sup>	Poland	1 male	TAC MMF Prednisone	ALT 55 U/L AST 18 U/L GGT 101 U/L Low CRP	Stopped MMF Lower prednisone dose	Alive
<b>Sessa A et al.</b> <sup>(50)</sup>	Italy	1 male	TAC	Lymphocytes 0.39 x10 <sup>9</sup> /L Platelets 122 000 / $\mu$ L ALT 28 U/L CRP 11.23 mg/dL	No change	Alive
<b>Waisberg DR et al.</b> <sup>(51)</sup>	Brazil	4 males 1 female	TAC (5) MMF (4)	Lymphocytes 0.87 x10 <sup>9</sup> /L WBC 16.99 x10 <sup>9</sup> /L ALT 133.4 U/L CRP 12.02 mg/dL	No change (2) Stopped MMF (2) Lower TAC dose (1) IS withdrawal (1)	3 alive 2 dead
<b>Mathiasen VD et al.</b> <sup>(52)</sup>	Denmark	1 female	TAC MMF	Lymphocytes 1.11 x10 <sup>9</sup> /L WBC 5.1 x10 <sup>9</sup> /L Normal ALT CRP 3.72 mg/dL	No change	Alive
<b>Kutzler HL et al.</b> <sup>(53)</sup>	USA	2 cases	TAC (2)	NS	No change	2 alive
<b>Mocchegiani F et al.</b> <sup>(54)</sup>	Italy	1 male	TAC	ALT 30 U/L AST 84 U/L	No change	Dead

<b>Goss MB et al.</b> <sup>(55)</sup>	USA	4 males 6 females	TAC (10) Prednisone (4) SIR (2) MMF (2)	Normal lymphocytes levels Low WBC in 2 cases	No change (9) Lower sirolimus dose (1) Lower TAC dose (1)	10 alive
<b>Imam A et al.</b> <sup>(56)</sup>	Turkey	3 males	TAC (3) Corticosteroids (3)	NS	NS	3 dead
<b>Heinz N et al.</b> <sup>(57)</sup>	USA	1 female	TAC MMF Methylprednisolone	Lymphocytes $4.5 \times 10^9/L$ WBC $18 \times 10^9/L$ ALT 980 U/L CRP 4.63 mg/dL	Stopped MMF Lower methylprednisolone dose Added prednisone	Alive
<b>Morand A et al.</b> <sup>(58)</sup>	France	1 female	TAC	ALT 3 U/L AST 4 U/L CRP 0.32 mg/dL	Lower TAC dose	Alive
<b>Lagana et al.</b> <sup>(59)</sup>	USA	1 female	MMF	ALT 1253 U/L AST 908 U/L GGT 473 U/L	IS withdrawal	Alive

\*The bold line separates the adult data (above the line) from the pediatric data (below the line).

ALT: alanine aminotransferase; AST: aspartate aminotransferase; AZA: azathioprine; CRP: C-reactive protein; EVE: Everolimus; GGT: gamma-glutamyltransferase; IS: immunosuppression; MMF: mycophenolate mofetil; MPA: mycophenolic acid; NS: not specified; SIR: sirolimus; TAC: tacrolimus; UK: United Kingdom; USA: United States of America; WBC: white blood cells.

## 5.2. Pediatric population

Regarding the pediatric population, seven (43.75%) were male, and nine (56.25%) were female. The mean age of the patients was 1.28 years ( $SD = 1.49$  years), ranging from 0.5 to 4.58 years. In 10 (62.5%) cases the age of the patient was not specified. Regarding the patient's race/ethnicity, seven (43.75%) were Hispanic, four (25%) White, and five (31.25%) were not specified. The mean time from liver transplantation to SARS-CoV-2 infection diagnosis was 3.50 years ( $SD = 4.80$ ), ranging from 0.01 to 18.01 years.

The most frequent cause for liver transplantation was biliary atresia ( $n = 5$ ; 31.25%), followed by cryptogenic cirrhosis ( $n = 1$ ; 6.25%), cholestatic liver disease ( $n = 1$ ; 6.25%), and hepatic adenomatosis ( $n = 1$ ; 6.25%). In 8 (50%) cases, the cause of liver transplantation was not specified. Obesity/overweight was the most common comorbidity, present in three (18.75%) cases, followed by AHT, diabetes mellitus, asthma and hepatoblastoma in two (12.5%) cases, and CKD, hypothyroidism and Ellis-van Creveld syndrome in one (6.25%) case. In five (31.25%) cases there were no comorbidities and in one (6.25%) case it wasn't specified. The most used baseline IS regimen in monotherapy or associated with another immunosuppressant was TAC ( $n = 15$ ; 93.75%), next to MMF ( $n = 4$ ; 25%), prednisone ( $n = 4$ ; 25%), corticosteroids ( $n = 3$ ; 18.75%), SIR ( $n = 2$ ; 12.5%), and methylprednisolone ( $n = 1$ ; 6.25%). Table 1 presents all pediatric demographic data.

Fever was identified as a primary symptom in eight (50%) cases, cough in six (37.5%) cases, SOB in four (25%) cases, diarrhea in three (18.75%) cases, chest pain in two (12.5%)

patients, and sore throat, rhinorrhea, headache, respiratory deterioration and nasal congestion in one (6.25%) patient. The time between the onset of COVID-19 symptoms to hospital admission varied between 0 and 3 days ( $M = 0.5$  days;  $SD = 1.12$ ). In 10 (62.5%) cases, it was not specified.

The only data regarding  $SpO_2$  was found in only two (12.5%) cases presenting 96% and 99% of peripheral oxygen saturation ( $M = 97.5\%$ ;  $SD = 2.12\%$ ). The values of hemoglobin were within the normal range in nine (56.25%) cases, lower in one (6.25%) case, and not specified in six (37.5%) cases. WBC count was normal in seven (43.75%) cases, higher in one (6.25%) patient (value of  $18 \times 10^9$  cells/L), lower in three (18.75%) cases, and not specified in five (31.25%) cases. Absolute lymphocyte count was normal in 11 (68.75%) cases, and not specified in five (31.25%) cases. The platelet count was normal in 10 (62.5%) patients, although not specified in the other six (37.5%) cases. ALT and AST were specified in only three patients, presenting values of 980, 3 and 1253 U/L ( $M = 743.33$  U/L;  $SD = 657,21$  U/L), and 908, 4 and 908 U/L ( $M = 606.67$  U/L;  $SD = 521,93$  U/L), respectively. In the other patients, ALT and AST values were not specified. GGT was also specified in the same three patients, with values of 656, 5 and 473 U/L ( $M = 378$  U/L;  $SD = 335,74$  U/L). In 15 (93.75%) patients tBRB was not specified. The only tBRB value presented was 3.6 md/dL. CRP was high in three (18.75%) patients, normal in four (25%) cases and not specified in nine (56.25%) other cases ( $M = 2.48$  mg/dL;  $SD = 2.16$  mg/dL). IL-6 was not specified in any of the patients. Finally, ferritin was normal in five (31.25%) cases, while not specified in the other 11 (68.75%) cases.

A total of five (31.75%) patients were admitted to the ICU. Regarding the management of the IS, it was withdrawn in one (6.25%) case, the dose was lowered in three (18.75%) cases, a new immunosuppressant was added in one (6.25%) case, not changed in nine (56.25%) cases and not specified in three (18.75%) cases. Azithromycin was added in four (25%) cases, followed by HCQ ( $n = 3$ ; 18.75%), other antibiotics ( $n = 2$ ; 12.5%), and immunoglobulin ( $n = 1$ ; 6.25%). In six (37.5%) cases no additional pharmacological therapy was prescribed, and in three (18.75%) cases it was not specified.

ECMO was necessary in three (18.75%) patients, CPAP in two (12.5%) patients, and 11 (68.75%) cases support ventilation was not necessary.

The most frequent complication during admission was ARDS ( $n = 3$ ; 18.75%), next to acute liver rejection ( $n = 2$ ; 12.5%), and hepatitis ( $n = 1$ ; 6.25%). No complications were found in 11 (68.75%) cases. In one (6.25%) patient the complications during hospital stay were not specified.

By the end, 13 (81.25%) patients were alive and three (18.75%) had passed away. The mean time for follow-up/hospital stay was 14.83 days ( $SD = 11.07$  days), ranging from 4 to 36 days. In 10 (62.5%) patients, this information was not specified.

Table 2 presents a summary of each clinical case.

## 6. DISCUSSION

In our study, we tried to identify prognosis factors for disease severity and worst outcome. As expected, older age was a poor outcome factor. This may be explained by physiological modifications typical of elderly people that cause frailty and susceptibility to more diseases. Another finding was that the severity and outcome were not affected by the time after LT. This hypothesis is because, since in most cases patients with a shorter time after LT are on higher doses of immunosuppressants, it led to more severe immunosuppression and, consequently, an increased disease severity. In a study conducted by Malekhosseini et al. in Iran,<sup>(60)</sup> he reported a total of 85 cases of COVID-19, being 66 from LT (77.65%), 16 from kidney transplantation (18.82%), two from kidney-pancreas transplantation (2.35%) and one from liver-kidney transplantation (1.18%). The average age of their patients was 46.4 years and the main comorbidities were diabetes (25.9%) and AHT (18.8%). Overall, 17 patients died which 21.9% were LT recipients. Although including some transplants other than liver, their results were very similar to ours (medium age of 58.73 years and overall death of 20%). However, the authors referred to an association between time after LT and the outcome: they reported that of five patients who had LT in under a month, four had died. Another point of view is presented by Belli et al.<sup>(61)</sup> and by Bhoori et al.<sup>(16)</sup> in their correspondence and by Merli et al.<sup>(62)</sup> in their letter to the editor. All concluded that mortality could be worse in patients with longer LT time. Both these associations were not found in our report ( $p=0.726$ ) as well as in other similar case series.<sup>(9, 63)</sup>

It is unanimous that the presence of comorbidities is associated with a poor outcome and/or disease severity. The most frequent comorbidities in our report were AHT and diabetes. This fact is similar in many other case series.<sup>(64)</sup> In our study, the only comorbidity associated with a worse prognosis was diabetes. In fact, in our report, the probability of a diabetic patient dying after being infected with SARS-CoV-2 is 7.63 higher than a non-diabetic patient. Diabetes is a multifactorial disease with long-term metabolic and vascular abnormalities and a higher susceptibility to infectious diseases. Insulin resistance and hyperglycemia result in a promotion of pro-inflammatory cytokines, oxidative stress and stimulate the production of mediators of tissue inflammation.<sup>(65)</sup> This pro-inflammatory status may be the underlying cause for this relation between diabetes and COVID-19.

A very interesting finding was that obesity/overweight was a protective factor for the worst outcome. Obesity/Overweight patients with COVID-19 have 12.54 more chance of being alive than patients with normal/low weight. This may be evidence for the “obesity survival paradox” (a higher severity of disease but a lower mortality rate in obese patients), which is present for other diseases such as pneumonia.<sup>(66)</sup> Although this relation is still very

controversial, some pathophysiological mechanisms can partially explain this phenomenon: a higher level of serum cholesterol may bind endotoxin and excess energy stored in adipose tissues, and probably others that are still unidentified.<sup>(66)</sup> A larger study focused on overweight and obese patients with COVID-19 should provide some help in understanding this relationship. CVD was not associated with a poor outcome. This finding was similar to an international European liver transplant recipient cohort by Becchetti et al.<sup>(12)</sup> who included 57 LT recipients infected with SARS-CoV-2.

Another very interesting finding was that MMF was associated with more complications and with shock. MMF is an antimetabolite drug that disrupts the making of RNA and DNA thus, preventing the replication of B and T lymphocytes.<sup>(18)</sup> When infected by SARS-CoV-2, patient's levels of these lymphocytes, plus NK cells, face a significant decrease in total number and, consequently, a dysregulation of immune response and are more prone to other infections and septic shock. In fact, this evidence is considered by some liver societies. British Transplant Society advocates that any LT recipient with a positive COVID-19 test should stop MMF.<sup>(67)</sup> The same position is taken by the Spanish Society of Liver Transplantation adding that, if MMF regimen is in monotherapy, a conversion to CNIs, mTOR inhibitors or steroids should be considered,<sup>(68)</sup> and by the American Association for the Study of Liver Diseases, which advises that all LT recipients should suspend or reduce the dose of MMF.<sup>(69)</sup>

It is evidenced in the literature that CNIs, especially cyclosporine, can cause AKI by strongly constricting the afferent renal arteriole, concomitantly, activating the renin-angiotensin-aldosterone system leading to an impaired renal function.<sup>(70)</sup> This may be the reason that in our work we found a positive association between cyclosporine and AKI. In this case, it is recommended to decrease cyclosporine dose or replace it with steroids to avoid graft rejection. A study led by Lee et al. from Recanati/Miller Transplantation Institute<sup>(28)</sup> with 38 LT recipients infected with SARS-CoV-2 reached the same association between CNIs and AKI.

Another conclusion that can be drawn is regarding the laboratory data. In our report, we found out that higher levels of WBCs and AST can be associated independently with a worse outcome. In a multicenter observational cohort study of 112 LT recipients with COVID-19, Rabiee and Sadowski et al.<sup>(64)</sup> revealed that liver injury is an independent factor for increased mortality. They showed that patients with a peak of liver enzymes during SARS-CoV-2 infection had a worse outcome. Although their focus was on ALT, for it is more specific to the liver than AST, they conclude that all liver enzymes should be closely monitored during hospital stay as they can predict a poor ending.

A pro-inflammatory state can also be associated with increased mortality and with a more severe course of the disease. This is supported by a positive association by increase WBCs levels and mortality and by higher levels of CRP and a higher complication rate. Moreover, lymphopenia was also associated with increased disease severity. The infection by

SARS-CoV-2 is known to create lymphopenia and, in a severe form of the disease, it is characterized by an excessive pro-inflammatory production mainly by IL-2, IL-7, IL-6 and TNF- $\alpha$ .<sup>(18, 71)</sup> This phenomenon, associated with an incompetent immune system, is responsible for the severity and mortality of this disease. Similar to our study, lymphopenia was present in many other series.<sup>(28, 60, 63, 72)</sup>

None of the specific pharmacological therapies were associated with the outcome in our study. Most of the patients in our series had done HCQ or lopinavir/ritonavir during hospital stay as a targeted therapy for COVID-19. Although guidelines now prove the ineffectiveness of these drugs, most of our cases were from the initial days of the pandemic and these two drugs were the first approved for SARS-CoV-2 infection. In fact, because of the interactions with the most used immunosuppressants, there is an increased risk for graft failure if the IS is not strictly regulated. Regarding the association between azithromycin and pneumonia, we interpret it as being used as a therapeutic since this antibiotic is used, in most cases, as first-line therapy.

In our study, 16.84% of the adult population was admitted to the ICU. In the study referred before, Malekhosseini et al.<sup>(60)</sup> reported a slightly higher ICU admission with 33.9% of cases. The authors also described a mortality of 20%, being the same in our study. In another series, Belli et al.<sup>(61)</sup> presented an ICU admission rate of 15% in his 103 LT recipients. He also reported that 66% of the patients required support ventilation (vs 44.21% in our work) and, of those, 15% needed invasive ventilation (vs 12.63%). His overall mortality rate for LT recipients was 16% (vs 20%). Finally, in a series by Coll et al.,<sup>(73)</sup> he reported a death rate of 22% between his 76 LT recipients. According to the WHO, the mortality rate of COVID-19 in the general population is 2.22%.<sup>(2)</sup> When comparing the overall mortality with the one from our study (2.22% vs 20%, respectively) we can conclude that LT recipients have a death rate nearly 10 times higher. This may be evidence that LT recipients with COVID-19 are at higher risk of dying.

We also included some pediatric patients in our study. However, because of the low number of cases and the missing data, no statistical conclusions were made. D'Antiga et al.<sup>(17)</sup> presented a study with 700 children on which only three were infected with SARS-CoV-2 and none died, concluded that the pediatric population was not at higher risk for disease severity and mortality. Another series from Italy led by Doná et al.<sup>(74)</sup> presented a European survey on transplantation centers that reported three LT recipients with COVID-19. All patients had mild symptoms and none died. In our study, the mortality rate was 18.75%. This overall mortality in the pediatric population must be taken carefully because only 16 single cases were analyzed and mortality was only present in one article. In this work, Imam et al.<sup>(56)</sup> presented three pediatric liver recipients with COVID-19. The first case was a 10-month-old male that, on day eight of post-operative, developed fever and SOB that causes the need for ECMO and the

patient eventually died. The second case was also a 10-month male that also developed fever and needed ECMO. In this case, a high level of liver enzymes and neutropenia was found. The final case was a 5-month male that needed ECMO for worsen respiratory function on day three and died on that same day.

COVID-19 is also known to cause myocardial lesions like atrial fibrillation, systolic/diastolic abnormalities and ischemic or non-ischemic cardiomyopathy, resulting from direct viral invasion, thromboembolism, STEMI and/or pro-inflammatory state. In fact, measuring the levels of troponins and BNP/Pro-BNP could help to identify these patients.<sup>(75)</sup> Myocardial lesion was absent in all of the cases analyzed for this research.

Another known fact of SARS-CoV-2 infection is that it may lead to long-term sequelae. The main long-term symptoms can be respiratory (cough, SOB), cardiovascular (palpitations, chest pain, thrombotic events), neurological (cognitive impairment, headache, peripheral neuropathic symptoms, delirium), general (fatigue, fever, pain), and others.<sup>(76)</sup> During our research period, no study on long-term complications in LT recipients was found. In our study, the follow-up varies between 1 day and 75 days ( $M = 21.7$  days). Therefore, accessing the main long-term complications by a close follow-up of the surviving patients could be a very interesting and important investigation.

Our study had some limitations. The main limitation was regarding the missing data. This may have contributed to an absence of association between some of the variables, for example, only 9 of 95 adult cases have platelet count and 48 of 95 have CRP serum value. In order to reduce the missing data, it is important to publish the complete clinical information, IS management, laboratory finds, as well as specific COVID-19 therapy, if available. A possible bias is related to only testing symptomatic patients or if risk contact with an infected patient during hospital stay. This fact may justify the overall increased mortality in LT recipients because, when comparing to the overall population, no mass screenings were conducted in this specific population resulting in an underdiagnosis of asymptomatic LT recipients.

In conclusion, older age and diabetes were independently associated with the worst outcome as well as a higher level of WBC and the need for support ventilation. In another hand, higher levels of CRP and lower levels of lymphocytes were associated with a more severe course of the disease. Obesity or overweight, interestingly, was associated with a lower death rate proving evidence of an “obesity survival paradox”. An important association between MMF as a baseline IS regimen and shock during hospital stay was found. No association between time after LT to COVID-19, specific antiviral therapy and outcome were found. Overall, liver transplantation recipients may be at higher risk of dying with the infection of SARS-CoV-2.



## 7. ACKNOWLEDGMENTS

I thank Dr<sup>a</sup>. Dulce Diogo and Dr<sup>a</sup>. Cristiana Marques for all their help and guidance on writing this manuscript.

To all my family, especially my mother Carla, my father Luís and my two siblings Catarina and João. To my grandmothers Liliana and Lúcia. To my grandfathers Luís and João. Thank you for letting me follow my dreams and be who I am.

To my friends, André, Brasil and Nunes, for being here every single day!

To all patients for their availability, which ultimately allowed the elaboration of this document.

To Angra do Heroísmo and to Coimbra.

## 8. REFERENCES

1. World Health Organization. Timeline: WHO's COVID-19 response 2020 [Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#!>]
2. World Health Organization. Coronavirus disease (COVID-19) pandemic: Numbers at a glance. 2020 [Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>].
3. Henriques G, Rato Nunes R, Henriques S. Portugal confirma dois casos de Covid-19 com ligações a Itália e Espanha Diário de Notícias: Diário de Notícias; 2020 [Available from: <https://www.dn.pt/pais/confirmados-dois-primeiros-casos-de-coronavirus-em-portugal-11805920.html>].
4. Diário da República. Decreto do Presidente da República n.º 14-A/2020. 2020. p. 13-(2-4).
5. Ministério da Saúde. Ponto de Situação Atual em Portugal 2020 [Available from: <https://covid19.min-saude.pt/>].
6. Imam A, Abukhalaf SA, Merhav H, Abu-Gazala S, Cohen-Arazi O, Pikarsky AJ, et al. Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review. *Ann Transplant*. 2020;25:e926196.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-62.
8. Nacif LS, Zanini LY, Waisberg DR, Pinheiro RS, Galvão F, Andraus W, et al. COVID-19 in solid organ transplantation patients: A systematic review. *Clinics (Sao Paulo)*. 2020;75:e1983.

9. Webb GJ, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. *Lancet Gastroenterol Hepatol.* 2020;5(11):1008-16.
10. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020;55(5).
11. Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. *J Clin Virol.* 2020;127:104392.
12. Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al. COVID-19 in an international European liver transplant recipient cohort. *Gut.* 2020;69(10):1832-40.
13. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Correction: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther.* 2020;5:61.
14. Jeannet R, Daix T, Formento R, Feuillard J, François B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. *Intensive Care Med.* 2020;46(9):1769-71.
15. Kumar D, Manuel O, Natori Y, Egawa H, Grossi P, Han SH, et al. COVID-19: A global transplant perspective on successfully navigating a pandemic. *Am J Transplant.* 2020;20(7):1773-9.
16. Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. *Lancet Gastroenterol Hepatol.* 2020;5(6):532-3.
17. D'Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl.* 2020;26(6):832-4.
18. Parente A, Manzia T, Angelico R, Tirota F, Muiesan P, Tisone G, et al. COVID-19, liver transplant, and immunosuppression: Allies or foes? *Transpl Infect Dis.* 2020;00:e13417.
19. article CttC. C4 article: Implications of COVID-19 in transplantation. *Am J Transplant.* 2020.
20. Boettler T, Newsome P, Mondelli M, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep* 2020;2(3):100113.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg.* 2010;8(5):336-41.
22. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant.* 2020;20(7):1849-58.

23. Zibiao Z. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients In: Qiuyan Z, Haoyang X, Aiping W, Wenjin L, Wei Z, Lihua Z, et al., editors. *Am J Transplant* 2020. p. 1916–21.
24. Qin J, Wang H, Qin X, Zhang P, Zhu L, Cai J, et al. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology*. 2020.
25. Huang JF, Zheng KI, George J, Gao HN, Wei RN, Yan HD, et al. Fatal outcome in a liver transplant recipient with COVID-19. *Am J Transplant*. 2020;20(7):1907-10.
26. Liu B, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. *Am J Transplant*. 2020;20(7):1891-5.
27. Hammami MB, Garibaldi B, Shah P, Liu G, Jain T, Chen PH, et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. *Am J Transplant*. 2020;20(8):2254-9.
28. Lee BT, Perumalswami PV, Im GY, Florman S, Schiano TD, Group CS. COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter. *Gastroenterology*. 2020;159(3):1176-8.e2.
29. Hoek RAS, Manintveld OC, Betjes MGH, Hellemons ME, Seghers L, Van Kampen JAA, et al. COVID-19 in solid organ transplant recipients: a single-center experience. *Transpl Int*. 2020;33(9):1099-105.
30. Kates OS, Fisher CE, Stankiewicz-Karita HC, Shepherd AK, Church EC, Kapnadak SG, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. *Am J Transplant*. 2020;20(7):1885-90.
31. Gao F, Zheng KI, Gu JY, George J, Zheng MH. COVID-19 and liver transplantation: Lessons learned from three reported cases. *Transpl Infect Dis*. 2020;22(4):e13335.
32. Verma A, Khorsandi S, Dolcet A, Prachalias A, Suddle A, Heaton N, et al. Low prevalence and disease severity of COVID-19 in post-liver transplant recipients - A single centre experience. *Liver Int*. 2020;40(8):1972-6.
33. Fung M, Chiu C, DeVoe C, Doernberg S, Schwartz B, Langelier C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. *Am J Transplant*. 2020;20(11):3225-33.
34. Müller H, Kniepeiss D, Stauber R, Schrem H, Rauter M, Krause R, et al. Recovery from COVID-19 following hepatitis C, human immunodeficiency virus infection, and liver transplantation. *Am J Transplant*. 2020;20(11):3255-6.
35. Patrono D, Lupo F, Canta F, Mazza E, Mirabella S, Corcione S, et al. Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy. *Transpl Infect Dis*. 2020;22(5):e13353.

36. John Hann A, Lembach H, McKay SC, Perrin M, Isaac J, Oo YH, et al. Controversies regarding shielding and susceptibility to COVID-19 disease in liver transplant recipients in the United Kingdom. *Transpl Infect Dis.* 2020;22(5):e13352.
37. Donato MF, Invernizzi F, Lampertico P, Rossi G. Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy. *Clin Gastroenterol Hepatol.* 2020;18(9):2131-3.e1.
38. Mehta SA, Rana MM, Motter JD, Small CB, Pereira MR, Stosor V, et al. Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. *Transplantation.* 2021;105(1):216-24.
39. Prieto M, Gastaca M, Ruiz P, Ventoso A, Palomares I, Rodríguez-Álvarez R, et al. A case of COVID-19 immediately after liver transplantation: Not only bad news. *Ann Hepatobiliary Pancreat Surg.* 2020;24(3):314-8.
40. Jamir I, Lohia P, Pande RK, Setia R, Singhal AK, Chaudhary A. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. *Ann Hepatobiliary Pancreat Surg.* 2020;24(4):526-32.
41. Eslami P, Moradi M, Dooghaie Moghadam A, Pirsalehi A, Abdul Lateef S, Hadaegh A, et al. Lethal outcome of Covid-19 pneumonia in a new liver recipient with neurological manifestation. *Gastroenterol Hepatol Bed Bench.* 2020;13(4):405-9.
42. García-Juárez I, Campos-Murguía A, Tovar-Méndez V, Gabutti A, Ruiz I. Unexpected better outcome in a liver transplant recipient with COVID-19: a beneficial effect of tacrolimus? *Rev Gastroenterol Mex.* 2020;85(4):437-42.
43. Hatami B, Ketabi Moghadam P, Zali M. Presentation of COVID-19 in a liver transplant recipient. *Gastroenterol Hepatol Bed Bench.* 2020;13(4):396-9.
44. Bösch F, Börner N, Kemmner S, Lampert C, Jacob S, Koliogiannis D, et al. Attenuated early inflammatory response in solid organ recipients with COVID-19. *Clin Transplant.* 2020;34(10):e14027.
45. Antony SJ, Singh J, de Jesus M, Lance J. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation. *IDCases.* 2020;21:e00888.
46. Loinaz C, Marcacuzco A, Fernández-Ruiz M, Caso O, Cambra F, San Juan R, et al. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. *Transpl Infect Dis.* 2020;22(5):e13372.
47. Modi AR, Koval CE, Taege AJ, Modaresi Esfeh J, Eghtesad B, Narayanan Menon KV, et al. Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. *Transpl Infect Dis.* 2020;22(5):e13351.

48. Felldin M, Søfteland JM, Magnusson J, Ekberg J, Karason K, Schult A, et al. Initial Report From a Swedish High-volume Transplant Center After the First Wave of the COVID-19 Pandemic. *Transplantation*. 2021;105(1):108-14.
49. Kolonko A, Dudzicz S, Wiecek A, Król R. COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation. *Transpl Infect Dis*. 2020:e13381.
50. Sessa A, Mazzola A, Lim C, Atif M, Pappatella J, Pourcher V, et al. COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report. *World J Gastroenterol*. 2020;26(44):7076-84.
51. Waisberg DR, Abdala E, Nacif LS, Haddad LB, Ducatti L, Santos VR, et al. Liver transplant recipients infected with SARS-CoV-2 in the early postoperative period: Lessons from a single center in the epicenter of the pandemic. *Transpl Infect Dis*. 2020:e13418.
52. Mathiasen VD, Oversoe SK, Ott P, Jensen-Fangel S, Leth S. Recovery of Moderate Coronavirus Disease 2019 in a Liver Transplant Recipient on Continued Immunosuppression: A Case Report. *Transplant Proc*. 2020;52(9):2703-6.
53. Kutzler HL, Poulos CM, Cheema F, O'Sullivan DM, Ali A, Ebcioğlu Z, et al. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut. *Transplantation*. 2021;105(1):e6-e8.
54. Mocchegiani F, Baroni GS, Vivarelli M. Mild impact of SARS-CoV-2 infection on the entire population of liver transplant recipients: the experience of an Italian Centre based in a high-risk area. *Updates Surg*. 2020;72(4):1291-3.
55. Goss MB, Galván NTN, Ruan W, Munoz FM, Brewer ED, O'Mahony CA, et al. The pediatric solid organ transplant experience with COVID-19: An initial multi-center, multi-organ case series. *Pediatr Transplant*. 2020:e13868.
56. Imam A, Karatas C, Imam R, Armutlu A, Mecit N, Karakaya A, et al. Three Consequent Pediatric Liver Transplant Deaths in the COVID-19 Era. *Int J Organ Transplant Med*. 2020;11(4):202-6.
57. Heinz N, Griesemer A, Kinney J, Vittorio J, Lagana SM, Goldner D, et al. A case of an Infant with SARS-CoV-2 hepatitis early after liver transplantation. *Pediatr Transplant*. 2020;24(8):e13778.
58. Morand A, Roquelaure B, Colson P, Amrane S, Bosdure E, Raoult D, et al. Child with liver transplant recovers from COVID-19 infection. A case report. *Arch Pediatr*. 2020;27(5):275-6.
59. Lagana SM, De Michele S, Lee MJ, Emond JC, Griesemer AD, Tulin-Silver SA, et al. COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation. *Arch Pathol Lab Med*. 2020.

60. Ali Malekhosseini S, Nikoupour H, Gholami S, Shamsaeefar A, Arasteh P, Kazemi K, et al. A Report of 85 Cases of COVID-19 and Abdominal Transplantation From a Single Center: What Are the Associated Factors With Death Among Organ Transplantation Patients. *Transplantation*. 2021;105(1):90-9.
61. Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. *Lancet Gastroenterol Hepatol*. 2020;5(8):724-5.
62. Merli M, Perricone G, Lauterio A, Prosperi M, Travi G, Roselli E, et al. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl*. 2020;26(11):1543-4.
63. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. COVID-19 in solid organ transplant: A multi-center cohort study. *Clin Infect Dis*. 2020.
64. Rabiee A, Sadowski B, Adeniji N, Perumalswami PV, Nguyen V, Moghe A, et al. Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience. *Hepatology*. 2020;72(6):1900-11.
65. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract*. 2020;162:108142.
66. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. *Eur J Med Res*. 2020;25(1):64.
67. British Transplantation Society, The Renal Association. Guidance on the management of transplant recipients diagnosed with or suspected of having COVID19 2020 [Available from: <https://bts.org.uk/wp-content/uploads/2020/07/Clinical-management-of-transplants-and-immunosuppression-updated-9th-July.pdf>].
68. Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. *J Hepatol*. 2021;74(1):148-55.
69. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. *Hepatology*. 2020;72(1):287-304.
70. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. *Transplant Proc*. 2004;36(2 Suppl):229S-33S.
71. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-4.

72. Yi SG, Rogers AW, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. *Transplantation*. 2020;104(11):2208-14.
73. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant*. 2020.
74. Doná D, Torres Canizales J, Benetti E, Cananzi M, De Corti F, Calore E, et al. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. *Clin Transplant*. 2020;34(10):e14063.
75. Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Heart Rhythm*. 2020;17(11):1984-90.
76. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ*. 2021;372:n136.